TrialBritish journal of haematology2015

TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.

Sanam Loghavi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.